VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CHE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CHEChemed Corporation
$546.75$7.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCHECash Flow

Chemed Corporation (CHE) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow margin has compressed sharply from 18.3% in Q4 2025 to just 5.5% in Q3 2026, with trailing ten-quarter buybacks of approximately $1.10B plus $78M in dividends outpacing $950.7M in cumulative operating cash flow and suggesting distributions are being supplemented by balance sheet reserves.

Income StatementBalance SheetCash FlowRatios

CHE Cash Flow Statement

Annual statement

CHE Cash Flow Statement

Chemed Corporation (CHE) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations363.15M388.27M417.5M330.3M309.89M308.6M489.29M301.25M287.14M162.5M135.39M171.5M110.28M150.85M131.77M174.34M86.01M160.83M112.08M99.58M98.59M80.01M94.16M22.59M29.52M34.36M51.84M27.5M20.8M33.4M35.8M
Operating CF Margin %-15.35%17.17%14.59%14.51%14.43%23.53%15.54%16.11%9.75%8.59%11.11%7.57%10.67%9.21%12.86%6.72%13.51%9.76%9.05%9.68%8.74%12.81%8.66%11.64%10.17%14.59%6.06%5.46%9.77%11.89%
Operating CF Growth %79.44%-7%26.4%6.59%0.42%-36.93%62.42%4.91%76.71%20.02%-21.05%55.51%-26.89%14.48%-24.42%102.7%-46.52%43.49%12.55%1.01%23.22%-15.02%316.8%-23.48%-14.08%-33.71%88.5%32.21%-37.72%-6.7%90.43%
Net Income282.4M265.24M302M272.51M249.62M268.55M319.47M219.92M205.54M98.18M108.74M110.27M99.32M77.23M89.3M85.98M81.83M73.78M71.02M63.98M50.65M35.82M27.51M-3.44M-1.81M-10.38M20.58M19.7M19.9M30.3M32.3M
Depreciation & Amortization67.59M64.84M63.05M60.87M59.17M59.05M56.58M45.2M38.86M35.63M34.64M33.5M33.07M32.39M30.52M29.5M29.04M27.9M27.5M26.57M23.8M23.34M20.18M12.81M14.36M24.12M23.45M20.1M17.3M15.2M18.8M
Stock-Based Compensation43.11M4.89M32.03M30.08M26.25M22.5M18.42M14.83M446K1.23M1.85M2.65M10.32M10.87M11.97M8.38M7.76M8.64M7.3M000000000000
Deferred Taxes9.86M-5.94M-4.14M-8.03M-3.35M-15.78M37.78M-2.77M5.19M2.41M-6.71M6.33M6.98M-6.99M-3.15M7.24M-2.41M4.98M426K8.11M7.41M-3.68M5M-501K855K-4.4M2.1M100K3.4M-1.8M-2.2M
Other Non-Cash Items-2.41M35.54M16.42M14.18M11.67M1.07M12.61M16.48M7.33M29.05M13.71M9.06M16.31M19.06M15.71M16.57M18.02M20.84M15.06M18.83M22.74M15.25M12.08M15.16M20.75M28.43M1.1M-2.4M-10.4M-15.1M-8.5M
Working Capital Changes-37.39M23.71M8.13M-39.31M-33.49M-26.8M44.43M7.58M17.15M-14.48M-25.18M4.79M-49.72M23.11M-8.75M26.68M-48.24M24.44M-4.61M-20.19M-6.02M6.85M28.44M661K-2.4M2.57M4.61M-10M-9.4M4.8M11.3M
Change in Receivables-38.5M-11.6M10.68M-41.49M-2.41M-8.43M12.77M-19.25M-5.57M1.07M-42.14M4.13M-45.78M-9.01M-24.42M26.9M-68.66M33.75M-6.66M000000000000
Change in Inventory490K650K3.83M-1.73M-162K-3.01M367K-1.76M-351K421K559K-142K535K355K1.61M-940K-151K29K-898K-18K-78K520K-986K1.24M931K79K-706K-500K-900K-800K5.8M
Change in Payables3.31M-5.19M-9.28M-9.35M15.34M9.83M19.1M28.42M8.94M12.89M891K476K-25.82M40.34M4.95M-1.4M13.81M-8.11M5.58M000000000000
Cash from Investing-163.37M-59.34M-143.91M-60.64M-59.4M-57.76M-61.56M-190.76M-105.22M-67.61M-39.86M-50.32M-43.53M-31.35M-40.68M-34.11M-35.7M-22.84M-28.63M-31.72M-27.73M-41.74M-353.21M-7.78M41.02M-19.09M-31.32M-32.2M-25.2M126M-84.4M
Capital Expenditures-67.7M-62.8M-49.53M-56.85M-57.33M-58.67M-58.83M-53.02M-52.87M-64.3M-39.77M-44.13M-43.57M-29.32M-35.25M-29.59M-25.64M-21.5M-26.09M-26.64M-21.99M-25.73M-18.29M-10.38M-8.44M-14.46M-31M-37.9M-36.8M-20.1M-11M
CapEx % of Revenue2.54%2.48%2.04%2.51%2.69%2.74%2.83%2.74%2.97%3.86%2.52%2.86%2.99%2.07%2.47%2.18%2%1.81%2.27%2.42%2.16%2.81%2.49%3.98%3.33%4.28%8.73%8.36%9.65%5.88%3.65%
Acquisitions-96.05M-225K-97.4M-3.99M-3.53M0-3.6M-138.01M-53.18M-4.72M0-6.61M-250K-2.26M-5.9M-3.66M-9.47M-1.92M-11.2M-1.08M-4.14M-6.17M-343.05M-3.85M-1.24M-1.55M00000
Investments-------------------------------
Other Investing383K3.68M3.02M206K1.45M918K871K272K824K1.42M-90K432K294K235K468K-858K-592K573K8.67M-4M-1.6M-9.84M8.13M-7.32M48.77M-4.45M-4.61M-2M-3.4M132M-115.9M
Cash from Financing-281.11M-432.77M-359.19M-79.83M-209.25M-380.62M-271.21M-109.16M-188.2M-99.08M-94.95M-120.59M-137.04M-104.61M-59.63M-152.06M-112.81M-29.2M-84.82M-92.15M-98.72M-52.59M279.81M-1.95M-41.53M-16.55M-27.52M-19.4M-25.1M-102.5M41.4M
Debt Issued (Net)245.87M10.97M-15.75M-81.75M-99.38M196.88M-90M800K-13.53M-850K16.76M-57.43M-29.74M-11.41M1.92M-826K-581K-19.98M-11.37M18.27M-81.99M-49.84M198.06M-1.02M-35.09M-11.38M-16.96M7M-2.9M-82.7M63.8M
Equity Issued (Net)-494.32M-404.35M-361.39M-67.7M-114.52M-576.04M-175.59M-92.63M-158.88M-94.64M-102.31M-59.32M-110.02M-92.91M-60.62M-143.97M-109.33M-4.22M-69.79M-131.7M-16.02M4.93M96.17M2.65M-1.67M-491K-5.73M-4.5M-400K0-3.7M
Dividends Paid-33.73M-31.7M-27.09M-23.5M-22.02M-22.02M-21.08M-19.79M-18.66M-17.37M-16.44M-15.61M-14.26M-14.15M-13.03M-12.54M-11.88M-8.16M-5.54M-5.89M-6.32M-6.17M-5.72M-4.76M-4.44M-4.38M-4.02M-22.5M-21.7M-21M-20.4M
Share Repurchases-524.6M-431.5M-361.39M-67.7M-114.52M-576.04M-175.59M-92.63M-158.88M-94.64M-102.31M-59.32M-110.02M-92.91M-60.62M-147.89M-109.33M-4.22M-69.79M-131.7M-19.89M-7.4M-2.65M-637K-3.21M-1.23M-5.73M-4.5M-400K0-3.7M
Other Financing1.07M-7.69M45.04M93.13M26.66M20.55M15.46M2.46M2.87M13.79M7.04M11.77M16.98M13.86M12.09M5.27M8.98M3.16M1.88M27.17M5.62M-1.5M-8.7M1.18M-343K-293K-806K600K-100K1.2M1.7M
Net Change in Cash-81.33M-103.83M-85.61M189.83M41.23M-129.78M156.52M1.33M-6.29M-4.19M583K595K-70.29M14.89M31.45M-11.84M-62.5M108.79M-1.36M-24.29M-27.86M-14.31M20.76M12.86M29.01M-1.27M-7M-24.1M-29.5M56.9M-7.2M
Free Cash Flow295.45M325.48M367.97M273.44M252.56M249.92M430.46M248.23M234.27M98.19M95.62M127.36M66.71M121.52M96.52M144.75M60.37M139.34M85.99M72.94M76.6M54.06M75.86M11.41M17.67M20.23M20.84M-10.4M-16M13.3M16.8M
FCF Margin %11.1%12.86%15.13%12.08%11.83%11.68%20.7%12.8%13.14%5.89%6.06%8.25%4.58%8.6%6.75%10.68%4.71%11.71%7.48%6.63%7.52%5.9%10.32%4.38%6.96%5.99%5.86%-2.29%-4.2%3.89%5.58%
FCF Growth %-18.03%-11.55%34.57%8.27%1.06%-41.94%73.41%5.96%138.57%2.69%-24.92%90.93%-45.11%25.91%-33.32%139.76%-56.67%62.04%17.88%-4.78%41.71%-28.75%564.78%-35.41%-12.66%-2.91%300.34%35%-220.3%-20.83%394.12%
FCF per Share22.4922.6124.2317.9916.7315.6826.2515.0213.945.875.707.313.746.544.996.912.626.133.682.912.872.063.080.570.891.041.05-0.49-0.790.660.85
FCF Conversion (FCF/Net Income)1.05x1.46x1.38x1.21x1.24x1.15x1.53x1.37x1.40x1.66x1.25x1.56x1.11x1.95x1.48x2.03x1.05x2.18x1.58x1.56x1.95x2.23x3.42x-6.58x-16.28x-3.31x2.52x1.40x1.05x1.10x1.11x
Interest Paid0000000000000000000000000000000
Taxes Paid0000000000000000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetFortress
Cash FlowDeteriorating
Top Statement Risk

Buybacks outpacing internal cash generation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Convert to Cash, But Timing Unreliable

Over ten quarters, Chemed generated $950.7M in operating cash flow against $707.9M in cumulative net income — a 34% premium suggesting solid earnings quality. However, the OCF-to-NI ratio swung from 2.64 to 0.46, indicating significant quarter-to-quarter conversion unpredictability that complicates forward cash flow forecasting.

The cumulative premium is partially explained by substantial non-cash D&A charges totaling approximately $164M across the period, but the wide quarterly dispersion — particularly the 0.46 ratio in Q1 2025 and 0.79 in Q3 2026 — suggests working capital timing and possibly Medicare receivable fluctuations are creating significant noise. Q3 2026's ratio of 0.79 was the second-lowest in the ten-quarter series and represented a sharp deterioration from the 1.30 recorded in the same quarter a year prior, which may indicate deteriorating collection dynamics or a growing accrual component in reported earnings. Investors should track whether the recent conversion weakness reflects a temporary timing artifact or signals a structural shift in the earnings-to-cash relationship.

Free Cash Flow Margins Sharply Compress

Chemed's free cash flow margin has declined from 18.3% in Q4 2025 to just 5.5% in Q3 2026 — the lowest reading since Q1 2025 — reflecting both a $26.8M year-over-year decline in operating cash flow and an $18.7M peak capex quarter, per the company's reported quarterly figures.

This compression is occurring even as net income remains relatively stable at $66–77M per quarter, suggesting the deterioration is driven by working capital drag and rising capital expenditure rather than an underlying operational deterioration. The sequential pattern from 18.3% to 10.8% to 10.3% to 5.5% across the last four quarters is concerning and departs sharply from the 2024Q4 peak of 23.8%. If this trajectory persists, the company's capacity to fund its aggressive buyback program from internal cash generation will be materially constrained, forcing a greater reliance on balance sheet drawdowns.

Working Capital Swings Dominate FCF Volatility

Quarterly working capital changes have swung from +$57.6M in Q2 2025 to -$52.6M in Q1 2025 — a range exceeding $110M that dwarfs underlying operating cash generation. As disclosed in Chemed's cash flow statements, these movements appear to be the single largest driver of free cash flow unpredictability across periods.

This pattern is consistent with the Medicare reimbursement and Cap reserve dynamics central to Chemed's accounting, where the timing of government payments and management-estimated reserve adjustments can create large non-operational cash swings that are difficult to forecast. Roto-Rooter's insurance billing cycle for water restoration work likely compounds the volatility, as service delivery and final cash collection may lag materially. The Q3 2026 working capital contribution of +$6.8M provided only marginal offset to the decline in operating cash flow, suggesting the recent FCF compression is not purely a working capital timing artifact and warrants closer examination of the underlying cash bridge.

Buybacks Have Outpaced Cash Generation

Over trailing ten quarters, Chemed deployed approximately $1.10B in share repurchases and $78M in dividends — totaling roughly $1.18B against $950.7M in cumulative operating cash flow, per Chemed's financial statements, suggesting internal cash generation alone has not fully funded the buyback pace and balance sheet reserves appear to supplement distributions.

The buyback cadence is highly irregular, swinging from $33.2M in Q1 2025 to $209.3M in Q4 2024, indicating opportunistic rather than programmatic repurchase execution tied to market conditions rather than cash availability. The Q1 2026 buyback of $190M coincided with the sharp FCF trough of $71.1M and a poor OCF/NI ratio of 0.46, suggesting management prioritized returning capital even during a weak cash generation quarter. With a fortress-level balance sheet and minimal leverage as noted in prior analysis, this drawdown is sustainable near-term, but the declining FCF trajectory across recent quarters suggests the buyback pace may need to moderate or become more opportunistic.

Stock Compensation Noise Masks Cash Reality

Chemed's stock-based compensation has exhibited extraordinary volatility, swinging from -$15.2M in Q3 2025 to $23.5M in Q4 2025 — a $38.7M range that materially distorts both reported earnings and the reconciling bridge between net income and operating cash flow, per recent SEC filings. This accounting noise warrants careful adjustment.

The negative SBC figure in Q3 2025 suggests reversal of prior expense recognition, potentially related to forfeitures or performance-based award adjustments, which would artificially depress OCF relative to NI in that period and make the 1.30 ratio misleading as a measure of operational cash quality. This accounting noise makes it difficult to isolate the true operational cash generation underlying the headline conversion ratios, and any forward cash flow model should apply normalized SBC assumptions. Additionally, the Medicare Cap reserve — a management-estimated liability — represents a judgment-laden adjustment that may introduce further non-cash volatility, and given the structural reimbursement ceiling facing the VITAS segment identified in prior analysis, the adequacy of this reserve warrants ongoing scrutiny.

CHE — Frequently Asked Questions

Quick answers to the most common questions about buying CHE stock.

How much cash does Chemed Corporation (CHE) generate from operations?

Chemed Corporation (CHE) generated $388.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Chemed Corporation's free cash flow?

Chemed Corporation (CHE) generated $325.5M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Chemed Corporation's capital expenditure (CapEx)?

Chemed Corporation (CHE) spent $62.8M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Chemed Corporation distribute cash to shareholders?

In 2025, Chemed Corporation (CHE) returned $31.7M to shareholders via cash dividends and spent $431.5M on share repurchases. This shows the company's commitment to returning capital to its equity investors.